Core Insights - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [3] - The company will participate in two upcoming investor conferences, providing opportunities for engagement with potential investors [1][2] Company Overview - Rapport Therapeutics specializes in discovering and developing small molecule precision medicines, leveraging its RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain [3] - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for the treatment of refractory focal epilepsy, bipolar mania, and diabetic peripheral neuropathic pain [3] - The company is also engaged in preclinical and late-stage discovery programs targeting chronic pain and hearing disorders [3]
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference